B
Description
Drug discovery company founded in 2015 in Durham, NC. Develops novel first-in-class oral small molecules for difficult-to-treat hematological and solid tumors, harnessing mitochondrial dynamics. Lead candidate: BTM-3566 for DLBCL. $25M seed funding.